234 related articles for article (PubMed ID: 22534009)
1. Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.
Samtani MN; Raghavan N; Shi Y; Novak G; Farnum M; Lobanov V; Schultz T; Yang E; DiBernardo A; Narayan VA;
Br J Clin Pharmacol; 2013 Jan; 75(1):146-61. PubMed ID: 22534009
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
3. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.
Skillbäck T; Kornhuber J; Blennow K; Zetterberg H; Lewczuk P;
J Alzheimers Dis; 2019; 69(2):551-559. PubMed ID: 31104027
[TBL] [Abstract][Full Text] [Related]
4. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.
Samtani MN; Farnum M; Lobanov V; Yang E; Raghavan N; Dibernardo A; Narayan V;
J Clin Pharmacol; 2012 May; 52(5):629-44. PubMed ID: 21659625
[TBL] [Abstract][Full Text] [Related]
5. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
6. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
7. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.
Davatzikos C; Bhatt P; Shaw LM; Batmanghelich KN; Trojanowski JQ
Neurobiol Aging; 2011 Dec; 32(12):2322.e19-27. PubMed ID: 20594615
[TBL] [Abstract][Full Text] [Related]
8. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
[TBL] [Abstract][Full Text] [Related]
9. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
[TBL] [Abstract][Full Text] [Related]
10. Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.
Michaud TL; Kane RL; McCarten JR; Gaugler JE; Nyman JA; Kuntz KM;
J Alzheimers Dis; 2015; 47(3):729-40. PubMed ID: 26401707
[TBL] [Abstract][Full Text] [Related]
11. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
[TBL] [Abstract][Full Text] [Related]
12. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
13. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
Llano DA; Laforet G; Devanarayan V;
Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
[TBL] [Abstract][Full Text] [Related]
15. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
[TBL] [Abstract][Full Text] [Related]
16. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
17. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
18. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.
Samtani MN; Raghavan N; Novak G; Nandy P; Narayan VA
Neuropsychiatr Dis Treat; 2014; 10():929-52. PubMed ID: 24926196
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
20. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
